Onyx Pharmaceuticals, a licensee of Ligand Pharmaceuticals, has gained FDA approval for Kyprolis (carfilzomib) for injection. Kyprolis is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have ...
Tags: Onyx Pharmaceuticals, Ligand Pharmaceuticals, Kyprolis
XTL Biopharmaceuticals has acquired 4,620,356 shares of Proteologics from Teva Pharmaceutical for nearly NIS6.5m($1.6m). The company has purchased single share at an amount of NIS1.405($0.36). The acquired shares represent all the ...
Tags: XTL Biopharmaceuticals, shares, drugs, multiple myeloma, schizophrenia
Acetylon Pharmaceuticals has received US patent covering fundamental composition of matter claims of the selective HDAC6 inhibitor, ACY-1215. ACY-1215T is at present being investigated in human trials to treat multiple myeloma. ...
Tags: US Patent, multiple myeloma, drug